Ernexa Therapeutics (ERNA) Change in Account Payables (2022 - 2024)
Historic Change in Account Payables for Ernexa Therapeutics (ERNA) over the last 3 years, with Q4 2024 value amounting to -$559000.0.
- Ernexa Therapeutics' Change in Account Payables fell 2791.76% to -$559000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$1.2 million, marking a year-over-year increase of 3114.29%. This contributed to the annual value of -$1.2 million for FY2024, which is 3114.29% up from last year.
- According to the latest figures from Q4 2024, Ernexa Therapeutics' Change in Account Payables is -$559000.0, which was down 2791.76% from $228000.0 recorded in Q3 2024.
- Ernexa Therapeutics' Change in Account Payables' 5-year high stood at $3.4 million during Q3 2022, with a 5-year trough of -$559000.0 in Q4 2024.
- For the 3-year period, Ernexa Therapeutics' Change in Account Payables averaged around $100.0, with its median value being -$437000.0 (2022).
- Per our database at Business Quant, Ernexa Therapeutics' Change in Account Payables tumbled by 11290.89% in 2023 and then soared by 15205.48% in 2024.
- Over the past 3 years, Ernexa Therapeutics' Change in Account Payables (Quarter) stood at -$437000.0 in 2022, then changed by 0.0% to -$437000.0 in 2023, then dropped by 27.92% to -$559000.0 in 2024.
- Its last three reported values are -$559000.0 in Q4 2024, $228000.0 for Q3 2024, and -$437000.0 during Q2 2024.